Breakthrough status for cancer drug


United States

The Roche Group has received a ‘breakthrough therapy designation’ from the US Food and Drug Administration for a new breast cancer treatment intended for patients with a PIK3CA mutation. The PIK3CA gene makes an enzyme which is involved in many important functions in a cell. Mutations can cause the enzyme to become overactive and cancer cells to grow.